CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (RLAY) (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing ...
Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the Company meaningfully past topline data for ReDiscover-2 trial and through ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results